胆汁淤积性肝病的治疗

doi:10.3969/j.issn.1672-5069.2016.06.004

Abstract

Yan Li，Ma Xiong.. Treatment of cholestastic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 650-653.

[1] Dong M，Li J，Tang R，et al. Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population. Clin Rev Allergy Immunol，2015，48（2-3）:316-321.
[2] Newton JL，Bhala N，Burt J，et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol，2006，44（4）:776-783.
[3] Quarneti C，Muratori P，Lalanne C，et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int，2015，35（2）:636-641.
[4] Beuers U，Kremer A E，Bolier R，et al. Pruritus in cholestasis: facts and fiction. Hepatology，2014，60（1）:399-407.
[5] Yang CY，Ma X，Tsuneyama K，et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy. Hepatology，2014，59（5）:1944-1953.
[6] Shi J，Wu C，Lin Y，et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:a meta-analysis of randomized controlled trials. Am J Gastroenterol，2006，101（7）:1529-1538.
[7] Zhang Y，Li S，He L，et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis. Drug Des Devel Ther，2015，9:2757-2766.
[8] Yin Q，Li J，Xia Y，et al. Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhosis. Drug Design，Develop Ther，2015，9:5407.
[9] Rautiainen H，Karkkainen P，Karvonen AL，et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial. Hepatology，2005，41（4）:747-752.
[10] Hirschfield G M，Mason A，Luketic V，et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology，2015，148（4）:751-761. e8.
[11] Nevens F，Andreone P，Mazzella G，et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. New Engl J Med，2016，375（7）:631-643.
[12] Zhu G Q，Shi K Q，Huang G Q，et al. A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis. Oncotarget，2015，6（29）:26757.
[13] Eksteen B. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. Bri Med Bull，2014:ldu008.
[14] Mizuno S，Hirano K，Isayama H，et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci，2015，22（10）:766-770.
[15] Bjoro K，Brandseater B，Foss A，et al. Liver transplantation in primary sclerosing cholangitis//Seminars in liver disease. Copyright 2006 by Thieme Medical Publishers，Inc. 333 Seventh Avenue，New York，NY 10001，USA.，2006，26（1）:069-079.
[16] Graziadei IW，Wiesner RH，Marotta PJ，et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology，1999，30（5）:1121-1127.
[17] Brandsaeter B，Friman S，Broome U，et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scan J Gastroenterol，2003，38（11）:1176-1183.
[18] Eaton J E，Talwalkar J A，Lazaridis K N，et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology，2013，145（3）:521-536.
[19] Lammert F，Marschall HU，Glantz A，et al. Intrahepatic cholestasis of pregnancy:molecular pathogenesis，diagnosis and management. J Hepatol，2000，33（6）:1012-1021.
[20] Bacq Y，Sentilhes L，Reyes H B，et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy:a meta-analysis. Gastroenterology，2012，143（6）:1492-1501.
[21] Gurung V，Stokes M，Middleton P，et al. Interventions for treating cholestasis in pregnancy. Cochrane Library，2013.
[22] Folvik G，Hilde O，Helge GO. Benign recurrent intrahepatic cholestasis:review and long-term follow-up of five cases. Scan J Gastroenterol，2012，47（4）:482-488.
[23] Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol，2012，36:S26-S35.
[24] Morotti RA，Suchy FJ，Magid MS. Progressive familial intrahepatic cholestasis（PFIC） type 1，2，and 3:a review of the liver pathology findings//Seminars in liver disease. Thieme Medi Publishers，2011，31（1）:003-010.
[25] Sambrotta M，Strautnieks S，Papouli E，et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nature Genet，2014，46（4）:326-328.
[26] Gonzales E，Taylor SA，Davit-Spraul A，et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology，2016[ahead of print].
[27] Gomez-Ospina N，Potter CJ，Xiao R，et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nature Commun，2016[ahead of print].
[28] Davit-Spraul A，Fabre M，Branchereau S，et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis（PFIC）: Phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology，2010，51（5）:1645-1655.
[29] Frider B，Castillo A，Gordo-Gilart R，et al. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3. Ann Hepatol，2015，14:745-751.
[30] Gonzales E，Grosse B，Schuller B，et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2:Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology，2015，62（2）:558-566.
[31] Zhang H，Bernuzzi F，Lleo A，et al. Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases. Mediat Inflammn，2015，2015.

Treatment of cholestastic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Qi, Zeng Ajuan, Meng Wen, et al.. Clinical analysis of cholecystopathy in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2019, 22(6): 924-927.
[2]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[3]	Ding Wenjin, Fan Jiangao.. Management of complications associated with cholestatic liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 938-940.
[4]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[5]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[6]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[7]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[8]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.
[9]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[10]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[11]	Zhu Yun, Yao Genhong, Tang Xiaojun. Mesenchymal stem cell transplantation alleviating hepatic injury by modulating intrahepatic biliary epithelial cell autophagic flux in mice with 2-OA-BSA-induced primary biliary cholangitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 337-340.
[12]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[13]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[14]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[15]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.